One more step towards unmet needs
One more step towards unmet needs
Bridge4Pharma offers scientific and strategic contribution to the advancement of pharmaceutical programs and products from early stage to registration.
Bridge4Pharma activities include assessment of innovative ideas and definition of tailored plans to achieve critical milestones.
Bridge4Pharma is also partnering in R&D projects and activities based on diagnostic, therapy and medical device technologies.
President and CEO
● 2023–today: President and CEO Bridge4Pharma S.r.l.
● 2020–2023: Head of RLT Research & Innovation and Head of R&D Ivrea Site, Novartis Institute for BioMedical Research (NIBR)
● 2009–2020: Head Research & Development/Head of Research & Innovation, Advanced Accelerator Applications S.A.S
● 2003–2000: General Manger Serono R&D Ivrea Site/Global Head Exploratory & Translational Medicine, Merck Serono S.A.
● 1996–2003: Global Head of Development, Galderma S.A.S.
● 1988–1996: Research & Development Manager, Menarini Pharmaceuticals S.r.l.
● 1991: Diploma of the American Board of Toxicology (DABT), Washington, USA
● 1990: Medical Specialty in General Pathology from La Sapienza University, Rome, Italy
● 1988: Ph.D. in Pharmacology from Temple University, Philadelphia, United States
● 1983: Degree in Medicine and Surgery from Sapienza University, Rome, Italy
CEO
● 2023–today: CEO Bridge4Pharma S.r.l.
● 2020–2023: Global Head of RLT Preclinical Development, Novartis Institute for BioMedical Research (NIBR)
● 2009–2020: Head of Preclinical Development/Clinical Pharmacology and Dosimetry, Advanced Accelerator Applications S.A.S.
● 2005–2009: PK/PD Scientist, Merck Serono S.A.
● 1998–2004: Research Scientist/Head of Delivery System and Process Development Dept, Istituto di Ricerca Cesare Serono
● 01/1998–06/1998: Student grant at University of Ljubljana, Faculty of Pharmacy (Pharmacokinetics)
● 02/1997–08/1997: Student grant at Centre for Polymer Therapeutics-School of Pharmacy, London (Polymer-drug conjugates for drug targeting in anticancer therapy)
● 1997: PhD in Pharmacy – Application of Experimental Design Methodology in the pre-formulation of solid dosage forms, University of Trieste, Italy
● 1994: Degree in Pharmaceutical Chemistry and Technology, University of Trieste, Italy
